학술논문

The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.
Document Type
Case Study
Source
BMC Infectious Diseases. 2/1/2021, Vol. 21 Issue 1, p1-6. 6p.
Subject
*THROMBOTIC microangiopathies
*COMPLEMENT inhibition
*ECULIZUMAB
*COMPLEMENT activation
*DIAGNOSIS
*T cells
Language
ISSN
1471-2334
Abstract
Background: The use of complement inhibition is well established for complement mediated thrombotic microangiopathy, but its role in secondary forms of thrombotic microangiopathy is debated. We here present a case of thrombotic microangiopathy triggered by Capnocytophaga canimorsus, illustrating the diagnostic difficulties in discriminating between different thrombotic microangiopathies, and the dilemmas regarding how to treat this disease entity.Case Presentation: A previously healthy 56-year-old woman presented with fever and confusion. She was diagnosed with sepsis from Capnocytophaga canimorsus and thrombotic microangiopathy. Marked activation of both T-cells, endothelium and complement were documented. She was successfully treated with antimicrobial therapy, the complement inhibitor eculizumab and splenectomy. After several weeks, a heterozygote variant in complement factor B was localized, potentially implying the diagnosis of a complement mediated TMA over an isolated infection related TMA.Conclusions: We discuss the possible interactions between complement activation and other findings in severe infection and argue that complement inhibition proved beneficial to this patient's rapid recovery. [ABSTRACT FROM AUTHOR]